These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20703211)

  • 1. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
    Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
    Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
    Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
    Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
    Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
    Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R
    Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients.
    Novoa PA; Grinyó JM; Ramos FJ; Errasti P; Franco A; Aldana G; Pefaur J; Marti-Cuadros AM; Otero AB; Saval N; Oppenheimer F
    Transplant Proc; 2011 Nov; 43(9):3331-9. PubMed ID: 22099791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
    Matz M; Lehnert M; Lorkowski C; Fabritius K; Unterwalder N; Doueiri S; Weber UA; Mashreghi MF; Neumayer HH; Budde K
    Transpl Int; 2012 Oct; 25(10):1106-16. PubMed ID: 22816666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of everolimus versus mycophenolate on blood and lymphocyte cyclosporine exposure in heart-transplant recipients.
    Gustafsson F; Barth D; Delgado DH; Nsouli M; Sheedy J; Ross HJ
    Eur J Clin Pharmacol; 2009 Jul; 65(7):659-65. PubMed ID: 19458944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy.
    Sánchez-Brotons JA; Sobrino-Márquez JM; Lage-Gallé E; Romero-Rodriguez N; Guisado A; Jiménez-Díaz J; Benezet-Mazuecos J; Arizón-Muñoz JM; Mogollón MV; Martínez A
    Transplant Proc; 2008 Nov; 40(9):3046-8. PubMed ID: 19010188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.
    Moscarelli L; Caroti L; Antognoli G; Zanazzi M; Di Maria L; Carta P; Minetti E
    Clin Transplant; 2013; 27(4):546-54. PubMed ID: 23758330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study.
    Potena L; Bianchi IG; Magnani G; Masetti M; Coccolo F; Fallani F; Russo A; Grigioni F; Branzi A; Ponticelli C
    Transplantation; 2010 Jan; 89(2):263-5. PubMed ID: 20098293
    [No Abstract]   [Full Text] [Related]  

  • 18. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H; Vitko S; Pascual J; Eris J; Magee JC; Whelchel J; Civati G; Campbell S; Alves-Filho G; Bourbigot B; Garcia VD; Leone J; Esmeraldo R; Rigotti P; Cambi V; Haas T;
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
    Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
    Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.